← All indications
Leukemia
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
Subtype terms (10)
More specific conditions that are subtypes of Leukemia in the MeSH hierarchy.
- Blastic Plasmacytoid Dendritic Cell Neoplasm
- Enzootic Bovine Leukosis
- Leukemia, Experimental
- Leukemia, Feline
- Leukemia, Hairy Cell
93 drugs (64 approved, 29 experimental)
- Leukemia, Lymphoid
167 drugs (93 approved, 74 experimental)
- Leukemia, Mast-Cell
27 drugs (20 approved, 7 experimental)
- Leukemia, Myeloid
101 drugs (65 approved, 36 experimental)
- Leukemia, Plasma Cell
50 drugs (36 approved, 14 experimental)
- Leukemia, Radiation-Induced
Drugs by status
Approved for this indication (14)
Phase 4 trials (28)
- idarubicin
- aprepitant
- cefepime
- thiotepa
- nicotine
- daunorubicin
- fludarabine
- ceftazidime
- sargramostim
- palonosetron
- prilocaine
- prednisolone
- vincristine
- methotrexate
- bupropion
- imatinib
- inotuzumab ozogamicin
- allogeneic hematopoietic stem cells
- Anti-thymocyte Globulin (Rabbit)
- Filgrastim
- cyclophosphamide
- amphotericin b
- tigecycline
- lidocaine
- cytarabine
- busulfan
- nilotinib
- granisetron
Phase 3 trials (118)
- ketamine
- azacitidine
- pr1 peptide
- hypericum perforatum
- palifermin
- aldoxorubicin
- oblimersen sodium
- epoetin
- tretinoin
- bendamustine
- bone marrow derived mononuclear cells
- quizartinib
- sorafenib
- blinatumomab
- ferrous sulfate
- erwinia asparaginase
- visilizumab
- insulin glargine
- Laromustine
- etoposide
- dactinomycin
- insulin lispro
- calaspargase pegol
- ofatumumab
- iron dextran
- chidamide
- calcium
- nelarabine
- autologous mesenchymal stem cells
- naltrexone
- +88 more
Phase 2 trials (255)
- vatalanib
- vnx-101
- t cell depleted hematopoietic stem cells
- glutathione
- autologous natural killer cells
- hydroxychloroquine
- acetylcysteine
- icosapent ethyl
- bms-986414
- fbta05
- tocilizumab
- pinometostat
- anti-minor histocompatibility complex (miha) donor t-lymphocytes
- cd56 car T cells
- amifostine
- ioa-244
- aclarubicin
- devimistat
- daratumumab
- lysergic acid diethylamide
- trimetrexate
- ibritumomab tiuxetan
- c144-ls
- il-3
- cd20 car-t cells
- theophylline
- carfilzomib
- p.dom-wt1-37 dna vaccine and p.dom-wt1-126 dna vaccine
- cilengitide
- allogeneic epstein-barr virus specific cytotoxic t-lymphocytes
- +225 more
Phase 1 trials (165)
- b43-genistein immunoconjugate
- at9283
- eth-155008
- lp-108
- cediranib
- Flotetuzumab
- a27.15
- y90 anti-cd19 monoclonal antibody bu12
- gti-2040
- treg-enriched donor cell
- autologous bone marrow derived mesenchymal cells
- car-37 t cells
- rifampin
- et019003-t cells
- phenethyl isothiocyanate
- cd22-specific car t-cells also expressing an egfrt
- mab-216
- ras peptide cancer vaccine
- cd19-tricar-t
- ina03
- triapine
- triciribine
- pyroxamide
- gilteritinib
- keyhole limpet hemocyanin
- cd19/cd22-dual-star-t
- cd19-tricar-silk
- gnkg168
- autologous humanized anti-cd19 and anti-cd20 dual specific car-t cells
- bmf-500
- +135 more
Organizations
Organization Involved with Phase 4 Indications (107)
- People's Liberation Army of China
- Medac
- Novartis
- Italian Association of Pediatric Hematology-Oncology
- Universidad Complutense de Madrid
- Soonchunhyang University
- Southeast University
- Pharmatech
- Gachon University
- East Valley Hematology and Oncology Medical Group
- Postgraduate Institute of Medical Education and Research
- Technical University of Dresden
- Jiao Tong University
- Tel Aviv University
- Johnson and Johnson
- Genzyme
- Medical Research Council
- Guangzhou Medical University
- Cornell University
- International BFM Study Group
- Shandong Provincial Hospital
- Danish Cancer Society
- Southern Medical University
- University of Valencia
- Genmab
- Soochow University
- Xiamen University
- Amgen
- University of Vienna
- Shandong Province Qianfoshan Hospital
- +77 more
Organization Involved with Phase 3 Indications (367)
- Riverside Haematology Group
- Bangladesh Medical University
- State University of New York, Buffalo
- National Heart, Lung, and Blood Institute (NHLBI)
- Karolinska Institute
- The Israeli CLL Study Group (ICLLSG)
- Ohio State University
- Rutgers University
- Hopital Americain
- University of Florence
- Jazz Pharmaceuticals
- University of Bern
- Cardiff University
- Novo Nordisk
- University of Perugia
- Physicians, Innovations, Science for Children Fund
- The First People's Hospital of Lianyungang
- Delta-Fly Pharma, Inc.
- University of Bologna
- Shengli Oilfield Central Hospital
- Temple University
- San Jorge Children's Hospital, Puerto Rico
- Dongguan Kanghua Hospital
- University of Cologne
- Instituto de Investigacion en Cancer de la Infancia y la Adolescencia
- Schering AG
- King Faisal Specialist Hospital
- Hacettepe University
- Amneal Pharmaceuticals
- Eastern Cooperative Oncology Group
- +337 more
Organization Involved with Phase 2 Indications (509)
- Bio-Path Holdings, Inc.
- Ewha Womans University
- Plexxikon
- Inovio Pharmaceuticals
- Simcere Pharmaceutical Co., Ltd
- Université catholique de Louvain
- Yeshiva University
- Epidemiological and Clinical Research Information Network
- GMP BIO Co., LTD.
- OncoTherapy Science, Inc.
- OBiS, Inc
- Department of Veteran Affairs
- OncoVista, Inc.
- North Shore Hospital, New Zealand
- GWT-TUD GmbH
- Academic and Community Cancer Research United
- Second Military Medical University
- Cell Therapy Catapult
- St. Baldrick's Foundation
- Kura Oncology, Inc.
- Medical University of South Carolina
- Cancer Biotherapy Research Group
- Race Oncology Ltd
- University of Leeds
- University of Palermo
- Sponsor GmbH
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
- Juno Therapeutics, Inc.
- Jin Yang Pharmaceutical
- University of Rennes
- +479 more
Organization Involved with Phase 1 Indications (204)
- HonorHealth Research Institute
- Thomas Helleday Foundation
- Cellex Patient Treatment GmbH
- JW Pharmaceutical
- Texas Tech University
- University of Science and Technology of China
- Georgia Institute of Technology
- Corixa
- Xencor
- Bharath Hospital and Institute of Oncology
- Parker Hughes Cancer Center
- Celularity, Inc.
- MingSight Pharmaceuticals Pty Limited
- Ludaopei Hospital
- ADIR Association
- Orca Biosystems, Inc.
- Atara Biotherapeutics
- Weifang People's Hospital
- Xeme Biopharma Inc.
- GenScript
- Pediatric Oncology Experimental Therapeutics Investigation Consortium
- Intrexon
- Boryung Pharmaceutical Company
- VioQuest Pharmaceuticals
- Immune-Onc Therapeutics Inc
- Igenica Biotherapeutics, Inc.
- Tianjin Mycure Medical Technology Co., Ltd
- miRagen Therapeutics, Inc.
- Newave Pharmaceutical Inc
- Oscotec Inc.
- +174 more
Organization Involved with Other Experimental Indications (30)
- Integrated Community Oncology Network
- Shengjing Hospital
- Australian and New Zealand Children's Oncology Group
- National Institute of Pediatrics
- University of Athens
- Children's Cancer Research Fund United States
- Federico Gomez Children's Hospital of Mexico
- Liaocheng People's Hospital
- Eligix
- Association for Training, Education, and Research in Hematology, Immunology, and Transplantation
- National Autonomous University of Mexico
- COALL Germany
- Upstate Carolina
- Thermo Fisher Scientific
- American Society of Clinical Oncology
- Leukosite
- Swiss National Science Foundation
- Linkoping University
- NOPHO Scandinavian countries
- Tawam Hospital
- United Kingdom Children's Cancer Study Group
- West Virginia University
- University of Mississippi
- Harokopio University
- Kantonsspital Aarau
- MacroGenics
- UWELL Biopharma
- University of Peloponnese
- Institut d'Hématologie et d'Oncologie Pédiatrique, Lyon
- Sinobioway Cell Therapy Co., Ltd.